A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Papillary Renal Cell Cancer Clinical Trial

Official title:

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02127710
• Other study ID #: D5082C00002
• Secondary ID: GU 111
• Status: Completed
• Phase: Phase 2
• Start date: April 30, 2014
• Est. completion date: April 20, 2020

Study information

• Verified date: March 2021
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single-arm, multicentre, global, phase II study designed to evaluate the efficacy and safety of AZD6094 in patients with papillary renal cell carcinoma (PRCC) who are treatment naïve or previously treated.

An independent central pathology review of tumour samples will be used to confirm the diagnosis of PRCC of all patients enrolling. However, locally available pathology results confirming PRCC will be allowed for timely study entry.

Description:

The study will comprise two stages. In Stage 1 approximately 20 patients will be enrolled. This group is considered sufficient to provide preliminary assessment of the anti-tumour activity of AZD6094 in the form of non-binding futility analysis.

If ≤ 2 tumour responses are observed in the first 20 evaluable patients termination of the study will be considered taking into account the relevant molecular profile of the patients and additional information from related studies in the drug development programme.

All patients entering the study will take AZD6094 600 mg by mouth (PO) once daily (QD). Treatment will be given continuously.

Following the baseline assessment, efficacy will be assessed by objective tumour assessments every 6 weeks (±7 days), for the first 12 months and every 12 weeks thereafter until objective disease progression as defined by RECIST v1.1 There will be a data cut-off after all patients have completed at least 12 weeks of treatment with AZD6094 or withdrawn. The database will be locked and data analysis will be performed on this dataset.

Any patients still receiving study drug at the time of data cut-off will be able to continue to receive AZD6094 while deriving clinical benefit. Such patients will continue to be monitored for the occurrence of serious adverse events up to 28 days after the last dose of AZD6094.

After database lock (DBL) tumour assessments will be performed every 12 weeks (±7 days) until objective disease progression as defined by RECIST v1.1.

Patients discontinuing treatment due to documented disease progression will enter a survival follow-up period, where they will be followed for the initiation of subsequent anti-cancer therapies every 3 months until death, loss to follow-up or withdrawal of consent, whichever comes first.

Patients discontinuing treatment prior to documented disease progression will enter a progression-free survival follow-up period where they will continue to have disease assessments every 6 weeks (±7 days) for the first 12 months of follow-up and every 12 weeks thereafter until objective disease progression as defined by RECIST v1.1, death, loss to follow-up or withdrawal of consent, whichever comes first. After DBL, tumour assessments will be performed in the progression free survival patient population every 12 weeks (±7 days) until objective disease progression as defined by RECIST v1.1

Recruitment information / eligibility

• Status: Completed
• Enrollment: 111
• Est. completion date: April 20, 2020
• Est. primary completion date: April 14, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 99 Years

Eligibility

Inclusion criteria

1. Provision of informed consent prior to any study specific procedures, sampling and analyses.

2. Histologically confirmed PRCC, which is locally advanced or metastatic.

3. Availability of an archival tumor sample or a pre-treatment fresh tumor sample for confirmation of PRCC by a central laboratory and other biomarker

4. Treatment naïve or have failed on previous treatment for PRCC. Previous treatments may include: targeted therapy (i.e. sunitinib, sorafenib, bevacizumab, pazopanib, temsirolimus, and everolimus), traditional immunotherapy (i.e. interferon-a, Interleukin-2), chemotherapy or a combination of chemoimmunotherapy.

5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

6. At least one lesion, not previously irradiated, and not chosen for a biopsy if performed during the screening period that can be accurately measured at baseline and which is suitable for accurate repeated measurements.

7. Adequate hematological function defined as:

1. Absolute neutrophil count =1500/µL

2. Haemoglobin =9 g/dL

3. Platelets =100,000/µL

8. Adequate liver function defined as:

1. Alanine aminotransferase and aspartate aminotransferase =2.5 x the upper limit of normal (ULN)

2. Total bilirubin =1.5 x ULN

9. Adequate renal function defined as glomerular filtration rate = 40 mL/min,

10. Adequate coagulation parameters, defined as International Normalisation Ratio <1.5 x ULN or activated partial thromboplastin time <1.5 x ULN.

11. Patients with known tumor thrombus or deep vein thrombosis are eligible if stable on low molecular weight heparin for =4 weeks.

12. Females should be using adequate contraceptive measures should not be breast feeding, and must have a negative pregnancy test prior to start of dosing if of childbearing potential or must have evidence of non-childbearing potential

13. Male patients should be willing to use barrier contraception, i.e. condoms.

14. Ability to swallow and retain oral medications.

15. Predicted life expectancy =12 weeks.

16. Aged at least 18 years.

17. Willingness and ability to comply with study and follow-up procedures.

18. Ability to understand the nature of this study and give written informed consent.

Exclusion criteria

1. Most recent chemotherapy, immunotherapy, chemo-immunotherapy, or investigational agents <21 days of the first dose of study treatment. Most recent targeted therapy <14 days of the first dose of study treatment.

2. Unresolved toxicities from any prior therapy greater than Common Terminology Criteria for Adverse Events Grade 1 at the time of starting study treatment with the exception of alopecia.

3. Prior or current treatment with a cMet inhibitor

4. Strong inducers or inhibitors of cytochrome P450 3A4 (CYP3A4), strong inhibitors of cytochrome P450 1A2 (CYP1A2), or CYP3A4 substrates with a narrow therapeutic range within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)

5. Wide field radiotherapy (including therapeutic radioisotopes such as strontium-89) administered =28 days or limited field radiation for palliation =7 days prior to starting study drug or has not recovered from side effects of such therapy

6. Major surgical procedures =28 days of beginning study drug or minor surgical procedures =7 days. No waiting is required following port-a-cath placement.

7. Previously untreated brain metastases.

8. Current leptomeningeal metastases or spinal cord compression due to disease.

9. Acute or chronic liver or pancreatic disease.

10. Uncontrolled diabetes mellitus.

11. Gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy

12. Any of the following cardiac diseases currently or within the last 6 months:

1. Unstable angina pectoris

2. Congestive heart failure (New York Heart Association = Grade 2)

3. Acute myocardial infarction

4. Stroke or transient ischemic attack

13. Inadequately controlled hypertension (i.e., systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) (patients with values above these levels must have their blood pressure controlled with medication prior to starting treatment).

14. Mean resting correct QT interval (QTc) >470 msec obtained from triplicate electrocardiagrams

15. Any clinically important abnormalities in rhythm, conduction or morphology of resting electrocardiograms, e.g. complete left bundle branch block, third degree heart block, second degree heart block, PR interval >250 msec.

16. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, hypokalaemia, congenital or familial long QT syndrome or family history of unexplained sudden death under 40 years of age or any concomitant medications known to prolong QT interval.

17. Currently receiving treatment with therapeutic doses of warfarin sodium. Low molecular weight heparin is allowed.

18. Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.

19. Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.

20. Presence of other active cancers, or history of treatment for invasive cancer =5years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.

21. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.

Related Conditions & MeSH terms

• Carcinoma, Renal Cell
• Papillary Renal Cell Cancer

Intervention

Drug:
• AZD6094
AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.

Locations

Country	Name	City	State
Canada	Research Site	Calgary	Alberta
Canada	Research Site	Edmonton	Alberta
Canada	Research Site	Toronto	Ontario
Canada	Research Site	Toronto	Ontario
Spain	Research Site	Barcelona
United Kingdom	Research Site	Cambridge
United Kingdom	Research Site	Glasgow
United Kingdom	Research Site	London
United Kingdom	Research Site	London
United Kingdom	Research Site	Manchester
United States	Research Site	Birmingham	Alabama
United States	Research Site	Boston	Massachusetts
United States	Research Site	Chicago	Illinois
United States	Research Site	Dallas	Texas
United States	Research Site	Detroit	Michigan
United States	Research Site	Duarte	California
United States	Research Site	Fort Myers	Florida
United States	Research Site	Houston	Texas
United States	Research Site	Iowa City	Iowa
United States	Research Site	Nashville	Tennessee
United States	Research Site	New York	New York
United States	Research Site	Palo Alto	California
United States	Research Site	Philadelphia	Pennsylvania

Sponsors (2)

Lead Sponsor	Collaborator
AstraZeneca	SCRI Development Innovations, LLC

Countries where clinical trial is conducted

United States,  Canada,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Objective Response Rate (RECIST Version 1.1)	The primary outcome measure was Objective Response Rate (ORR), defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to Response Evaluation Criteria for Solid Tumours (RECIST) v1.1.	Up to 12 months
Primary	Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Efficacy Analysis Set	The primary outcome measure was ORR, defined as the proportion of patients with either a complete response or a partial response by investigator assessment according to RECIST v1.1.	12 Months
Primary	Objective Response Rate (RECIST Version 1.1) Stratified by c-MET Status in Safety Analysis Set	The primary outcome measure was ORR, defined as the proportion of patients with either a confirmed complete response/partial response by investigator assessment according to RECIST v1.1.	12 Months
Secondary	Progression Free Survival Stratified by c-MET Status in the Efficacy Analysis Set		Up to 12 months
Secondary	Overall Survival Stratified by c-MET Status in the Efficacy Analysis Set		Up to 12 months
Secondary	Progression Free Survival Stratified by c-MET Status in the Safety Analysis Set		Up to 12 months
Secondary	Overall Survival Stratified by c-MET Status in the Safety Analysis Set		Up to 12 months
Secondary	Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Efficacy Analysis Set	12 week summary for patients in the Efficacy analysis set, by MET status. The numbers of patients analysed represent the numbers evaluable at the 12 week timepoint.	12 Weeks (at 12 weeks timepoint)
Secondary	Change From Baseline in Target Lesion Tumour Size at 12 Weeks in Safety Analysis Set.	12 week summary for patients in the Safety analysis set by MET Status. The number of patients analysed represent the number of evaluable patients at the 12 week timepoint.	12 Weeks (at 12 week timepoint)
Secondary	Duration of Response	Duration of Response is the time from the first documentation of confirmed complete response/partial response until the date of progression, or death in the absence of progression. There were 8 responders: one of whom subsequently progressed or died and seven of whom were still classified as responders at the time of data cut-off and were therefore censored. It was not possible to determine a median or 75th percentile.	Up to 12 months
Secondary	Peak Plasma Concentration of AZD6094 Following Single Dose	The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.	24 Hours
Secondary	Time to Peak Plasma Concentration of AZD6094 After Single Dose	The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.	24 Hours
Secondary	Apparent Volume of Distribution of AZD6094 Following Single Dose	The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.	24 Hours
Secondary	Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose	The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.	24 Hours
Secondary	Area Under Plasma Concentration Time Curve for AZD6094 After Single Dose (Time Zero to Last Measurement)	The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.	24 Hours
Secondary	Apparent Total Clearance of AZD6094 From Plasma After Single Dose	The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.	24 Hours
Secondary	Mean Residence Time of AZD6094 After Single Dose	The number of patients analysed represent the number of evaluable PK parameters for this endpoint.	24 Hours
Secondary	Elimination Half-Life of AZD6094 After Single Dose	The number of patients analysed represent the number of patients with evaluable PK parameters for this endpoint.	24 Hours

External Links

•   D5082c00002-revised-csp-3_Redacted